BioCardia, Inc. (BCDA)
Automate Your Wheel Strategy on BCDA
With Tiblio's Option Bot, you can configure your own wheel strategy including BCDA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCDA
- Rev/Share -0.0119
- Book/Share -0.3279
- PB -6.1607
- Debt/Equity -0.5592
- CurrentRatio 0.3627
- ROIC 8.4824
- MktCap 10459338.0
- FreeCF/Share -1.7516
- PFCF -1.2881
- PE -1.116
- Debt/Assets 0.3924
- DivYield 0
- ROE -307.9266
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia's CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.
Read More
Insider Buying Surges in May. Especially These 5 Stocks
Published: May 07, 2025 by: 24/7 Wall Street
Sentiment: Neutral
The Securities Act of 1934 established many of the US rules for the securities market in the aftermath of the 1929 Stock Market Crash that ushered in The Great Depression.
Read More
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
Published: April 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress
Read More
BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
Published: March 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT.
Read More
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on or after September 30, 2034.
Read More
About BioCardia, Inc. (BCDA)
- IPO Date 1996-11-13
- Website https://www.biocardia.com
- Industry Biotechnology
- CEO Dr. Peter A. Altman Ph.D.
- Employees 17